CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

SOPHiA GENETICS Q3 2026 net loss widens to USD 20.27 million; Q3 2026 revenue rises 25% to USD 24.27 million

By Public Technologies
  • SOPHiA GENETICS’ third-quarter 2026 net loss widened to USD 20.27 million.
  • Revenue rose 25% year-over-year to USD 24.27 million.
  • The company signed 30 new core genomics customers and closed three material BioPharma deals.
  • Full-year 2026 revenue is expected at the upper end of the previously issued USD 94 million–USD 96 million guidance range.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611030645PR_NEWS_USPR_____NE87113) on November 03, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk